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Low-Molecular-Weight Heparin Dosage in Newborn Foals
L. Armengou, L. Monreal, M.A´. Delgado, J. Rı´os, C. Cesarini, and E. Jose-Cunilleras
Background: Heparin is used in humans as prophylaxis of hypercoagulable states and disseminated intravascular coagu-
lation (DIC). However, babies need a higher heparin dose than do adults. Septic neonate foals are at high risk of
hypercoagulable state and DIC, and there is limited objective information about heparin dose for equine neonates.
Objective: To assess whether neonate foals require higher dosages of low-molecular-weight heparin (LMWH) than adults.
Animals: Eighteen healthy and 11 septic neonate foals.
Methods: Experimental and clinical studies. Firstly, healthy foals were randomly distributed in 2 groups, 1 receiving 50 IU/
kg SC of dalteparin and the 2nd group receiving 100 IU/kg SC of dalteparin, once daily for 3 days. Blood samples were collected
before and 3, 6, 27, and 51 hours after the 1st LMWH administration. Plasma antifactor-Xa activity was measured, together
with hemostatic and hematologic parameters used to assess the risk of bleeding. Subsequently, septic foals were treated blindly
either with placebo (saline) or 100 IU/kg of dalteparin for 3 days. Plasma antifactor-Xa activity and other hemostatic param-
eters were determined before and after treatment.
Results: Plasma antifactor-Xa activity in healthy foals was below prophylactic activity when using the adult dosage (50 IU/
kg), whereas prophylactic activities were achieved when using the double dosage (100 IU/kg). No hemorrhagic events and
erythrocyte-related complications were observed with either dosage. In the clinical study, only 4/6 septic foals had plasma an-
tifactor-Xa activity adequate for prophylaxis.
Conclusions and Clinical Importance: Equine neonates require higher dosages of LMWH compared with adults to reach
prophylactic heparinemia.
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Sepsis, the systemic inﬂammatory response to infec-tion, is one of the leading causes of death in human
intensive care unit patients1 and newborn foals.2
Humans with severe sepsis can have coagulation abnor-
malities consistent with disseminated intravascular
coagulation (DIC),3–5 which is a major factor inﬂuenc-
ing mortality in septic human neonates.3,6 There is
clinical evidence in septic human neonates of an associa-
tion between DIC and renal failure.7 Furthermore,
humans with DIC have histopathologic changes consis-
tent with necrosis and intravascular thrombi in vessels of
various organs due to ﬁbrin deposition.8 Although there
is controversy among authors, some have proposed
that DIC and consequent ﬁbrin deposition contribute to
organ failure.9,10
The relationship between septicemia and coagulopathy
consistent with thrombotic events and DIC also has been
detected and studied in critical equine neonate patients.
Septicemia is an important disease and the most common
cause of death in neonate foals.11 The incidence of co-
agulopathies consistent with DIC in septic foals is up to
50% and it is associated with poor outcome.12,13 More-
over, massive ﬁbrin deposition and microthrombosis in
capillaries of the main organs, such as lung, kidney, and
liver, have been observed in most septic foals that died or
were euthanized because of poor prognosis in a single
study population,14 and this massive ﬁbrin deposition
might be associated with the multiorgan failure syndrome
according to similar results in other articles.15,16
In recent years, low-molecular-weight heparins
(LMWHs) have become one of the anticoagulant drugs
used in human pediatric patients, both for primary
thromboprophylaxis and the treatment of thromboembo-
li.17–19 In horses, heparin therapy has been recommended
to treat the hypercoagulable state and DIC associated
with severe gastrointestinal tract diseases and endo-
toxemia in adults, and septicemia in newborn foals.20–22
Other thrombotic events such as venous thrombosis and
thrombophlebitis have been also treated with hep-
arin.20,21,23 Moreover, it has been observed that LMWH
therapy reduces ﬁbrin deposition in capillaries of horses
with severe inﬂammatory gastrointestinal tract disease.24
From the Servei de Medicina Interna Equina, Departament deMe-
dicina i Cirurgia Animals, Facultat de Veterina`ria, Universitat
Auto`noma de Barcelona, Barcelona, Spain (Armengou, Monreal,
Delgado, Cesarini, Jose-Cunilleras); and Laboratory of Biostatistics
& Epidemiology, Universitat Auto`noma de Barcelona, Statistics and
Methodology Support Unit, IDIBAPS, Hospital Clı´nic, Barcelona,
Spain (Rı´os). The manuscript represents a portion of a thesis submit-
ted by the ﬁrst author at the Universitat Auto`noma de Barcelona as
partial fulﬁlment of the requirements for her PhD program, supervised
by the corresponding author.
Corresponding author: Luis Monreal, DVM, PhD, Dipl ECEIM,
Servei de Medicina Interna Equina, Departament de Medicina i
Cirurgia Animals, Facultat de Veterina`ria, Universitat Auto`noma de
Barcelona, 08193 Bellaterra, Barcelona, Spain; e-mail: lluis.monreal
@uab.es.
Submitted October 13, 2009; Revised May 20, 2010; Accepted
June 11, 2010.
Copyright r 2010 by the American College of Veterinary Internal
Medicine
10.1111/j.1939-1676.2010.0568.x
Abbreviations:
ADP adenosine diphosphate
ADP-CT adenosine diphosphate closure time
aPTT activated partial thromboplastin time
AT antithrombin
CT closure time
DIC disseminated intravascular coagulation
LMWH low-molecular-weight heparin
PT prothrombin time
J Vet Intern Med 2010;24:1190–1195
Human neonates require higher doses of LMWH com-
pared with older children and adults to reach adequate
prophylactic concentrations.19,25 Prophylactic concentra-
tions are those that prevent thromboembolic disease in
at-risk patients. LMWH therapy should reach a range of
0.1–0.3 IU/mL antifactor-Xa activity for prophylactic
purposes in humans.26,27 A pharmacokinetic study on
LMWH in horses demonstrated that their pharmacoki-
netic and anticoagulant properties are similar to those in
people.28 A dose of 50 IU/kg of LMWH (dalteparin) in
adult horses can be adequate for prophylactic purposes.29
Pharmacokinetics of LMWH in equine neonates and the
dosage needed to reach the prophylactic levels of plasma
antifactor-Xa activity have not been determined.
Similar to human neonates, equine neonates have some
coagulation system peculiarities that might have inﬂu-
enced LMWH pharmacokinetics. Based on human pedia-
tric studies, the dose of LMWH for newborn foals might
need to be doubled compared with the dose recommended
for adult horses. Thus, the main objective of the present
study was to compare 2 different doses of LMWH (the
one recommended in adult horses and a double dose) in a
population of healthy neonatal foals, in order to assess
which of these 2 doses reached prophylactic levels of
plasma antifactor-Xa activity. A 2nd objective was to as-
sess whether hemorrhagic risks and erythrocyte-related
complications were detected in neonates when the pro-
phylactic dose of LMWH was reached. Finally, plasma
antifactor-Xa activity also was determined in a group of
septic neonate foals receiving LMWH, in order to assess
whether the activity was affected by sickness.
Materials and Methods
Animals
In the experimental study, 18 Andalusian healthy newborn foals
from a farm nearby the Equine Teaching Hospital of Barcelona
were used, with the owner’s informed consent. Foals were deter-
mined to be healthy based on clinical history, complete physical
examination, and results of additional tests that included measure-
ments of serum IgG concentration, hematology, ﬁbrinogen
concentration, and sepsis score. Foals did not receive any medica-
tion before or during the study except for LMWH.
Additionally, in the prospective clinical study, those septic neo-
nate foals hospitalized at the Equine Teaching Hospital of
Barcelona between February and June 2009, from which their own-
ers’ consent was obtained, were enrolled. The diagnosis of sepsis
was conﬁrmed by either a positive blood culture, conﬁrmed septic
polyarthritis, sepsis score 14,30 or postmortem conﬁrmation.
Experimental Study Design
Healthy foals were randomly assigned to 2 groups. One group
received the same dose of LMWH as adults (50 IU/kg of daltep-
arina) once daily, for 3 days; whereas the 2nd group received a
double dose of 100 IU/kg of dalteparin once daily, for 3 days. All
injections were given SC in the scapular region.
Blood samples were drawn before starting on LMWH (T-0), 3
and 6 hours after the 1st treatment (T-3 and T-6), and 3 hours after
the following daily treatments (T-27 and T-51). Samples were col-
lected from the jugular vein into 3 vacuum-evacuated tubes,b 1
containing K3EDTA and 2 citrated (1 : 9, citrate : blood), and im-
mediately refrigerated in a portable refrigerator and processed
within 2 hours after sampling. Blood samples collected in EDTA
were used for hematologic determinations. One citrated blood tube
was centrifuged for 15 minutes at 1,000  g, and plasma was re-
moved and frozen at 201C within 2 hours in several aliquots until
analyzed for hemostatic variables. The 2nd citrated blood sample
was used for assessment of platelet function by determination of
closure time (CT) within 3 hours of sampling.
PCV was measured by the microhematocrit method. Hemoglo-
bin concentration and platelet count were determined with a
semiautomatic cell counter.c Assessment of erythrocyte agglutina-
tion was performed by microscopic examination of blood (5mL)
diluted with saline solution (5 drops), as described elsewhere.29,31,32
Agglutination was then graded (grade 0–3) as previously used29
(grade 0 5 no agglutination, grade 1 5 mild erythrocyte agglutina-
tion, grade 2 5 moderate agglutination, and grade 3 5 severe
agglutination).
Activated partial thromboplastin time (aPTT) and prothrombin
time (PT) were determined in duplicate, with a semiautomatic co-
agulometerd and coagulometric kits,d as reported previously.12
Platelet function inhibition was assessed with a platelet function
analyzer (PFA-100)e and the determination of the CT with adeno-
sine diphosphate (ADP) as the platelet agonist (adenosine
diphosphate-closure time [ADP-CT]). The system has been de-
scribed in detail elsewhere33,34 and used previously in horses.35
ADP-CT was determined before treatment (T-0) and 3 hours after
daily treatment of the 1st and 3rd day (T-3 and T-51, respectively).
Finally, heparin concentration in plasma was measured using the
antifactor-Xa activity assayd by a colorimetric method in a semiau-
tomatic analyzer.f
Clinical Study Design
Once the experimental study was ﬁnished and analyzed, a clinical
study was designed in order to assess whether plasma antifactor-Xa
activity achieved in healthy neonates after LMWH therapy was
similar to that achieved in sick neonates. Therefore, a double blind,
randomized, prospective study was designed. The investigator per-
forming randomization did not have any information of the sick
foals, and coded syringes were given to senior clinicians as soon as
an eligible septic foal was hospitalized.
After diagnosis and initial therapy, septic foals were randomly
assigned to 2 groups. With the information about antifactor-Xa
activity of the experimental study, a decision was made to not assess
the 50 IU/kg dose in septic foals. Therefore, 1 group received
100 IU/kg of LMWH (dalteparin) and the other received placebo
(saline at the same volume). Placebo was included to compare po-
tential adverse effects with the LMWH group and to conﬁrm the
lack of antifactor-Xa activity in nontreated foals. Both treatments
were administered SC daily, for 3 days, and foals were daily mon-
itored for assessing any adverse effect associated with LMWH
therapy. Foals whose LMWH treatment could not be ﬁnished (due
to euthanasia performed before ﬁnishing the treatment period) or
did not have a conﬁrmed diagnosis of sepsis were excluded.
Blood samples were drawn through the jugular catheter, and
placed in citrated tubes. They were collected just before treatment
(T-0) and 3 hours after each daily treatment (T-3, T-27, and T-51,
respectively). Samples were processed identically as samples in the
experimental study. In this case plasma antifactor-Xa activity was
measured after the same technique as in the experimental study, and
clotting times, antithrombin (AT) activity and D-Dimer concentra-
tion were additionally determined by techniques described
previously.12
Statistical Analysis
Commercial software (SPSS, 15.0 version)g was used for all
the statistical analyses. In the experimental study, a longitudinal
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General Linear Model that considered the intraindividual variabil-
ity for the levels of studied parameters was used to evaluate the
differences between treatment groups at each sample time for all the
hematological and hemostatic variables assessed. An unstructured
working matrix for the estimation of foals’ intravariability was
used.
Results were expressed as estimated means and their standard
deviation (SD) for each time of follow-up and, only for description
purposes, the median also was used in the text. In the clinical study,
a Wilcoxon test for paired measures was used to compare differ-
ences of plasma antifactor-Xa activity and hemostatic parameters
before and after treatment. For the clinical study, results were
expressed as median and interquartile range. For statistical signiﬁ-
cance, a type I error was set at 0.05 (2-tailed) for all analyses.
Results
Experimental Study
Eight healthy foals were included in the adult dose
group (50 IU/kg), whereas 10 healthy foals were enrolled
in the double dose group (100 IU/kg). In the 50 IU/kg
group, 6 foals were males and 2 were females. Their mean
 SD age was 5.5  5.5 days (median, 4 days). In the
100 IU/kg group, there were 7 females and 3 males. Their
mean  SD age was 6.9  7.0 days (median, 3.5 days).
Only the high-dose group (100 IU/kg) achieved plasma
heparin concentrations above 0.1 IU/mL (measured by
antifactor-Xa activity) (Table 1 and Fig 1). Antifactor-
Xa activity in the high-dose group (100 IU/kg) increased
signiﬁcantly (Po .001) compared with baseline (T-0) at
all time points; whereas in the adult dose group (50 IU/
kg) it increased signiﬁcantly (Po .005) only at T-51, but
did not reach the minimum prophylactic antifactor-Xa
activity (0.1 IU/mL)26,27 during treatment. Mean antifac-
tor-Xa activities in the high-dose group (100 IU/kg) were
Table 1. Hematological and coagulation variables in healthy foals (n5 18) treated with the adult-dose (50 IU/kg) and
the doubled dose (100 IU/kg), just before initiating LMWH treatment, at 3 and 6 hours after the 1st treatment, and at 3
hours after treatment on the 2nd and 3rd day (27 and 51 hours).
Variables Before Therapy 3 Hours 6 Hours 27 Hours 51 Hours
PCV (%)
50 IU/kg 36.0  3.1 34.6  3.9 33.5  3.6# 34.5  3.3 33.4  3.0#
100 IU/kg 36.3  5.7 33.9  5.1# 36.5  6.0 36.1  7.0 35.0  5.0#
Hemoglobin (g/dL)
50 IU/kg 13.7  1.3 12.9  1.4 13.0  1.2 12.6  1.2# 12.5  1.1#
100 IU/kg 13.5  2.9 12.9  2.1 13.3  1.9 12.9  2.0# 12.9  2.0#
Platelet count (x103/mL)
50 IU/kg 243.7  101.0 224.1  64.6 223.6  28.3 227.6  78.5 217.2  61.1
100 IU/kg 248.7  130.2 219.0  100.5 207.5  104.8 238.0  134.4 234.9  142.2
aPTT (s)
50 IU/kg 51.0  8.4 57.5  16.8 53.5  8.1 52.9  7.3 50.4  8.5
100 IU/kg 53.0  9.4 57.0  8.4 55.7  6.1 52.1  5.4 52.6  3.9
PT (s)
50 IU/kg 12.6  1.0 13.1  1.7 13.1  1.4# 12.6  1.0 12.4  0.7
100 IU/kg 13.8  1.7 13.7  1.6 13.8  1.3 13.1  0.7 13.2  0.9
ADP-CT (s)
50 IU/kg 69.4  12.7 76.5  15.9 — — 70.1  19.8
100 IU/kg 66.2  18.5 75.2  21.6 — — 94.7  73.3
Antifactor-Xa (IU/mL)
50 IU/kg 0  0 0.012  0.027 0.002  0.005 0.007  0.021 0.024  0.023#
100 IU/kg 0  0 0.126  0.063# 0.099  0.047# 0.132  0.063# 0.121  0.096#
Results are presented as mean  SD.
Signiﬁcantly different from the 50 IU/kg group at the same sample time.
#Signiﬁcantly different from baseline (before treatment).
Fig 1. Plasma antifactor-Xa activities for doses of low-molecular-
weight heparin (LMWH) of 50 and 100 IU/kg in the experi-
mental study (n 5 18) at each sampling time: just before initiating
LMWH therapy (0 hours), 3, and 6 hours after the 1st treatment,
and 3 hours after daily treatment for the next 2 days (27 and 51
hours). Horizontal dashed line indicates minimum prophylactic an-
tifactor-Xa activity. Results are presented as mean and standard
deviation.
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signiﬁcantly higher (Po.001) when compared with those
in the 50 IU/kg group at all sampling times during treat-
ment. Although mean values of the high-dose group
(100 IU/kg) were above the minimum prophylactic anti-
factor-Xa activity (0.1 IU/mL), some individuals did not
reach this minimum value during treatment.
Sixty-eight out of 72 samples from both groups had
absent or mild red cell agglutination. Only 3 samples of
the adult dose group (50 IU/kg) and 1 sample of the high-
dose group (100 IU/kg) showed an agglutination grade
higher than 1. No relationship between this mild agglu-
tination and the dosage of heparin administered was
detected.
PCV decreased mildly but signiﬁcantly (Po.05) in
both treatment groups when compared with those values
before treatment (T-0), although values always stayed
within reference range (Table 1). Hemoglobin concentra-
tion also decreased mildly but signiﬁcantly at T-27 and
T-51 in both groups compared with baseline samples. No
differences were observed for platelet count, aPTT and
ADP-CT (Table 1). Statistical differences were observed
for PT during treatment, although values remained
within normal limits. No other variations were detected.
None of the foals showed swelling at the injection site.
Only foal #15 (belonging to the high-dose group) had
signs of either jugular hematoma or phlebitis from the 1st
sampling because of difﬁculties in this foal’s management
and subsequent repeated sampling. No other adverse
effects related to treatment or sample collection were de-
tected in any foal.
Clinical Study
Eleven septic foals were ﬁnally enrolled in the prospec-
tive study, of which 5 foals received placebo (saline) and
6 foals received heparin therapy. Four other foals were
excluded because the initial clinical diagnosis of sepsis
was not conﬁrmed, and another 4 septic foals were also
excluded because they died or were euthanized before
ﬁnishing the treatment period. Foals receiving placebo
were 3 males and 2 females, with a mean  SD age of 0.7
 0.4 days (median, 1 day). They were 3 Andalusians, 1
Lusitanian, and 1 Arabian. Foals receiving LMWHwere
4 males and 2 females, with a mean SD age of 6.7 6.8
days (median, 4.5 days). They were 2 Andalusians, 2
Arabians, and 2 Warmblood foals.
No adverse effects associated with LMWH therapy
were observed in these foals. Antifactor-Xa activity was
always absent at all sampling times in the placebo group,
whereas it increased signiﬁcantly (P o .05) at T-3 com-
pared with baseline in the LMWH group (Table 2).
Median activities at T-27 and T-51 did not reach statis-
tically differences compared with baseline.
Discussion
In the present study, healthy neonate foals required
double dose of LMWH (100 IU/kg of dalteparin) of
adult horses to reach the same prophylactic plasma anti-
factor-Xa activity. Septic foals in the LMWH group
reached prophylactic plasma antifactor-Xa activity, and
some foals did not reach prophylactic activities at all the
sample times. Therefore, results of this study demon-
strate that newborn foals require higher doses of LMWH
than do adults for thromboprophylaxis; however, the
ﬁnal recommended dose for septic foals remains to be
determined.
LMWHs are known to cause fewer hemostatic altera-
tions and bleeding risks than unfractioned heparins in
humans.19,36 LMWH did not cause thrombocytopenia or
inhibit platelet function in foals in the present experi-
mental study. Moreover, LMWH did not cause
prolongation of clotting times in foals in both experi-
mental and clinical studies, even at the dose of 100 IU/kg,
which is in agreement with other studies where LMWH
at a regular adult dose did not affect platelet count,
Table 2. Plasma antifactor-Xa activity, clotting times (aPTT and PT), D-Dimer concentration, and antithrombin ac-
tivity (AT) in septic foals treated with the dose of 100 IU/kg dalteparin (n5 6) or placebo (n5 5), just before initiating
therapy and at 3 hours after treatment during 3 days (3, 27, and 51 hours).
Variables Before Therapy 3 Hours 27 Hours 51 Hours
Antifactor-Xa (IU/mL)
Placebo 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
100 IU/kg 0 (0–0) 0.07 (0.03–0.24)# 0.08 (0.02–0.17) 0.1 (0.02–0.21)
aPTT (s)
Placebo 84.8 (75.4–95.1) 87.1 (67.9–111.1) 78.7 (60.2–87.6) 64.4 (55.8–95.5)
100 IU/kg 59.0 (57.6–102.5) 68.4 (55.6–93.8) 74.8 (54.6–93.1) 64.5 (52.3–85.5)
PT (s)
Placebo 15.4 (13.0–17.0) 20.0 (15.2–23.0) 15.8 (14.5–18.5) 14.0 (13.5–19.1)
100 IU/kg 15.3 (12.0–19.0) 17.8 (12.1–25.9)# 16.4 (13.0–21.5) 14.1 (12.6–18.8)
D-Dimer (ng/mL)
Placebo 278 (255–426) 432 (209–1462) 603 (396–3720) 1722 (557–4015)
100 IU/kg 474 (300–1583) 341 (312–2519) 564 (314–1499) 922 (361–1707)
AT (%)
Placebo 134 (118–151) 138 (116–155) 157 (140.5–181) 168 (147–182)
100 IU/kg 154 (117.5–205.5) 159 (118–191) 168 (108.5–185.5) 169 (105.5–189)
Results are presented as median, interquartile range.
#Signiﬁcantly different from baseline (before treatment).
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clotting times, and template bleeding time.29,37,38 Thus,
no increased risk of bleeding was associated with
LMWH at the higher dose used in this study. Other stud-
ies in adult horses also demonstrated that LMWH has
little or no effect on PCV, erythrocyte count, and hemo-
globin concentration of treated horses.22,29 The mild
decrease observed in PCV and hemoglobin concentra-
tion compared with baseline values in the present study
was statistically signiﬁcant but clinically irrelevant, since
none-to-mild erythrocyte agglutination was observed. A
higher number of foals might help to determine whether
this decrease was related to LMWH or due to familiar-
ization of the foals to repeated sampling.
None of the foals of this study showed any complica-
tion or adverse effect related to treatment when giving
LMWH at 100 IU/kg, except 1 foal in the experimental
study that had mild signs of either jugular hematoma or
phlebitis due to difﬁculties in that foal’s management and
repeated sampling. Difﬁcult management was considered
the main cause of the mild jugular complication seen, be-
cause it was already observed immediately after the 1st
sampling and before LMWH treatment.
This study had some limitations. Originally, the exper-
imental study was designed as a cross-over design, in
which each foal would have received both doses of
LMWH (50 and 100 IU/kg) during their neonatal period
(o21 days) in a randomized fashion. Eventually, this de-
sign could not be followed mainly because most foals
unfortunately were sold or moved to different facilities
before ﬁnishing the cross-over study, but also because the
hemostatic system could have variations associated with
age during the neonatal period.39 This fact could produce
some bias on the results when comparing foals at 2 differ-
ent ages. In this study, differences seen on the hemostatic
tests could be caused by either age or treatment, and both
effects would have been indistinguishable. One possibil-
ity to reduce the bias related with age could be to treat all
foals at 2 ﬁxed ages. However, movements of animals out
of the study made it impossible.
In the clinical study, the actual age difference between
placebo and LMWH treated septic foals due to random
allocation is worth noting. The small number of cases
made unpractical the subclassiﬁcation of the foals ac-
cording to age. Therefore, the physiologic hemostatic
differences that foals of different ages had might slightly
affect the results reported.
Another limitation could be related to the sampling
times chosen. The possibility that peak plasma antifac-
tor-Xa activities occurred before or after sampling time
(3 and 6 hours after LMWH administration) cannot be
ruled out, and the possibility that the 100 IU/kg group
reached prophylactic activities before or after sampling
exists. However, sampling design was decided using in-
formation from previous studies, in which peak plasma
activity was measured between 2 and 6 hours.17 Thus, al-
though not impossible, it seems certainly improbable
that signiﬁcantly higher antifactor-Xa activities would
have been missed in the present study.
Finally, in the clinical study plasma antifactor-Xa ac-
tivity increased in the LMWH group during treatment.
However, because of the low number of septic foals re-
cruited and the variability of antifactor-Xa activity seen
in some neonates, the results only were statistically sig-
niﬁcant at T-3 (3 hours) compared with baseline. Most of
the variability seen in the LMWH group was mainly be-
cause of 1 foal that never reached prophylactic
antifactor-Xa activity. Interestingly, this foal had the
lowest AT activity at all time points, which was proba-
bly the cause of its low antifactor-Xa activity and
subsequently contributed to the variability seen. More-
over, clinical signs such as epistaxis and multiple
petechiae, clinicopathological results and postmortem
ﬁndings such as multiple petechiae and echymosis in
different organs, and different thrombi conﬁrmed a se-
vere DIC status in that foal. Regarding the hemostatic
proﬁle in the clinical study, no relevant differences were
detected comparing baseline values and treatment values.
Hemostatic proﬁle of these septic animals showed similar
alterations to those reported previously.11–13 A prospec-
tive randomized clinical study with a larger group of
animals is warranted in order to conﬁrm tendencies seen
in this preliminary clinical trial, as well as to assess the
effect of heparin therapy on outcome.
In conclusion, newborn foals need higher doses of
LMWH than adult horses in order to reach the plasma
antifactor-Xa activity level of LMWH recommended for
thromboprophylactic therapy. Its administration at a
dose of 100 IU/kg in foals is safe and did not produce
bleeding risks, thrombocytopenia or erythrocyte aggluti-
nation. Further studies are warranted to determine the
recommended dose for thromboprophylaxis in septic
foals.
Footnotes
a Fragmin, Kabi Pharmacia AB, Stockholm, Sweden
bVenoject, Terumo Europe, Leuven, Belgium
cAdvia 120 Analyzer, Bayer Lab, New York, NY
d Stago ST4, Stago Diagnostics, Asnie`res-Sur-Seine, France
e PFA-100 System, Siemens Healthcare Diagnostics, Deerﬁeld, IL
fOlympus AU400, Olympus Diagnostics, Hamburg, Germany
g SPSS Inc, Chicago, IL
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